← Back to headlines
340B Program Changes May Boost Biosimilar Uptake
Proposed changes to the 340B drug pricing program could shift prescribing patterns towards lower-cost biosimilars, as reforms may make hospitals more price-sensitive, reducing their large spreads on branded drugs.
10 Aug, 13:54 — 10 Aug, 13:54
